Authors: Mario Bonomini, Annalisa Giardinelli, Caterina Morabito, Sara Di Silvestre, Moreno Di Cesare, Natalia Di Pietro, Vittorio Sirolli, Gloria Formoso, Luigi Amoroso, Maria Addolorata Mariggiò, Assunta Pandolfi
DOI: 10.1371/journal.pone.0030682
Abstract Summary
Calcimimetics like R-568, used to treat hyperparathyroidism, may benefit blood vessels through mechanisms independent of their primary calcium-sensing receptor (CaSR) target. Research on human endothelial cells revealed that while CaSR protein is present, functional receptors are largely absent. Both R-568 and its mirror form increased intracellular calcium and nitric oxide release equally—suggesting CaSR-independent vascular effects.
Why Brain? 🧠
Calcimimetics used to treat hyperparathyroidism increase nitric oxide release in human endothelial cells through a mechanism independent of their known calcium-sensing receptor target, suggesting additional vascular benefits.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
